Clinical trial
Capecitabine in Treating Patients With Metastatic Breast Cancer
NCT00274768 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00274768 |
|---|---|
| Title | Capecitabine in Treating Patients With Metastatic Breast Cancer |
| Official title | Phase II Study of Fixed-Dose Capecitabine in Metastatic Breast Cancer |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | capecitabine |
| Enrollment | 26 |
| Start date | Apr 1, 2004 |
| Primary completion | Dec 1, 2009 |
| Completion | Nov 1, 2012 |
| First posted | Jan 11, 2006 |
| Last update posted | Jan 27, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: